{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:14:57Z","timestamp":1790356497097,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41591-025-03547-4","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:04:24Z","timestamp":1741601064000},"page":"1379-1380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Rare Therapies Launchpad: a pilot program for individualized medicines in the UK"],"prefix":"10.1038","volume":"31","author":[{"given":"Daniel J.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7054-4711","authenticated-orcid":false,"given":"Michael","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Blackwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-8211","authenticated-orcid":false,"given":"Matthew A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deb","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-5704","authenticated-orcid":false,"given":"Jenny","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-7701","authenticated-orcid":false,"given":"Tim","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Vitarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"3547_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ajmg.c.32029","volume":"193","author":"TW Yu","year":"2023","unstructured":"Yu, T. W. et al. Am. J. Med. Genet. C Semin. Med. Genet. 193, 7\u201312 (2023).","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"3547_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/d41573-023-00145-2","volume":"22","author":"DJ O\u2019Connor","year":"2023","unstructured":"O\u2019Connor, D. J., Gabaldo, M., Aartsma-Rus, A. & Hechtelt Jonker, A. Nat. Rev. Drug Discov. 22, 857\u2013858 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3547_CR3","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1056\/NEJMe1911295","volume":"381","author":"J Woodcock","year":"2019","unstructured":"Woodcock, J. & Marks, P. N. Engl. J. Med. 381, 1678\u20131680 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3547_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41591-024-03071-x","volume":"30","author":"JMY Pian","year":"2024","unstructured":"Pian, J. M. Y. et al. Nat. Med. 30, 1816\u20131818 (2024).","journal-title":"Nat. Med."},{"key":"3547_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","volume":"24","author":"AH Jonker","year":"2025","unstructured":"Jonker, A. H. et al. Nat. Rev. Drug Discov. 24, 40\u201356 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3547_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-021-01380-z","volume":"27","author":"A Aartsma-Rus","year":"2021","unstructured":"Aartsma-Rus, A. Nat. Med. 27, 939 (2021).","journal-title":"Nat. Med."},{"key":"3547_CR7","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3547_CR8","unstructured":"Office for Health Sciences. Genome UK: The Future of Healthcare (UK Government, 2020)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03547-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03547-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03547-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:00:48Z","timestamp":1747753248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03547-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3547"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03547-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"10 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.O.C. is employed by a pharmaceutical industry trade association. M.W. is a co-founder of and consultant for Pepgen Limited. M.M. is founder and chair of Rosa Genomic Medicines, non-executive director of Autolus Therapeutics PLC, chair of investment committee L&G UK Universities Ventures LP and non-executive director of Synairgen PLC. N.B. is chair, Genomics England; chair, Oxford University Innovation; director, supervisory board, BioNTech SE; and senior independent non-executive director, RTW Biotech Opportunities Ltd (a full list of her interests can be accessed here: ). M.A.B. is a consultant for Altis Medicines, Grey Wolf Therapeutics, Incyte and Ipsen and has research funding from UCB. D.L. is a trustee of Myeloma UK. T.Y. has received research support for an N=1 trial in ataxia telangiectasia from EveryONE Medicines and is named as an inventor on three patents pertaining to antisense oligonucleotide treatments: for transposon-associated diseases (WO2019055460A1), ataxia telangiectasia (US20230174979A1) and progranulin (US11359199B2); he has also received scientific consulting fees as pertains to ASO therapies from SynaptixBio, RegUp, Servier Pharmaceuticals and Lilly, serves as an unpaid board member for the N=1 Collaborative, the Oligonucleotide Therapeutics Society and the Society for RNA Therapeutics, and is an unpaid scientific advisor to several rare disease foundations. J.V. is a co-founder and unpaid board member of the N=1 Collaborative, a co-founder and consultant for EveryONE Medicines and an unpaid board member for several rare disease foundations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}